PR Newswire | Nov 17, 2020 04:06PM EST

11/17 15:05 CST

Dynavax to Present at the 3rd Annual Evercore Virtual ISI HealthCONx Conference EMERYVILLE, Calif., Nov. 17, 2020

EMERYVILLE, Calif., Nov. 17, 2020 /PRNewswire/ -- Dynavax Technologies Corporation (NASDAQ: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that Ryan Spencer, Chief Executive Officer, will participate in a virtual fireside chat at the 3rd Annual Evercore virtual ISI HealthCONx Conference on Thursday, December 3, at 10:05 a. m. E.T.

The live audio webcast may be accessed through the "Events & Presentations" page on the "Investors" section of the Company's website at www.dynavax.com. A replay of the webcast will be available for 30 days following the live event.

About DynavaxDynavax is a commercial stage biopharmaceutical company developing and commercializing novel vaccines. The Company's first commercial product, HEPLISAV-B(r) [Hepatitis B Vaccine (Recombinant), Adjuvanted], is approved in the U.S. for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older. Dynavax is also advancing CpG 1018 as a premier vaccine adjuvant through global research collaborations and partnerships. Current collaborations are focused on adjuvanted vaccines for COVID-19, pertussis and universal influenza. For more information, visit www.dynavax.com and follow the company on LinkedIn.

Contacts:

Nicole Arndt, Senior Manager, Investor Relations narndt@dynavax.com510-665-7264

Derek Cole, PresidentInvestor Relations Advisory Solutions derek.cole@IRadvisory.com

View original content to download multimedia: http://www.prnewswire.com/news-releases/dynavax-to-present-at-the-3rd-annual-evercore-virtual-isi-healthconx-conference-301175311.html

SOURCE Dynavax Technologies